BR112017020606A2 - ?composições e métodos de uso de peptídeos de interleucina-10 e anticorpos anti-interleucina? - Google Patents

?composições e métodos de uso de peptídeos de interleucina-10 e anticorpos anti-interleucina?

Info

Publication number
BR112017020606A2
BR112017020606A2 BR112017020606A BR112017020606A BR112017020606A2 BR 112017020606 A2 BR112017020606 A2 BR 112017020606A2 BR 112017020606 A BR112017020606 A BR 112017020606A BR 112017020606 A BR112017020606 A BR 112017020606A BR 112017020606 A2 BR112017020606 A2 BR 112017020606A2
Authority
BR
Brazil
Prior art keywords
interleukin
methods
antibody
compositions
peptide
Prior art date
Application number
BR112017020606A
Other languages
English (en)
Inventor
Ellen Rieman Jane
Marshall Sand Jordan
Eric Cook Mark
Marie Raabis Sarah
Mary Mcguirk Sheila
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BR112017020606A2 publication Critical patent/BR112017020606A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pediatric Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

a presente invenção refere-se a métodos para reduzir um sintoma de doença respiratória em um mamífero alimentado com leite pré-desmamado administrando-se oralmente um anticorpo isolado que se liga especificamente ao peptídeo de interleucina-10 ou a um anticorpo anti-interleucina-10. além disso, são incluídos métodos para reduzir o estresse de mistura em mamíferos humanos e não humanos administrando-se um anticorpo isolado que se liga especificamente ao peptídeo de interleucina-10 ou a um anticorpo anti-interleucina-10. são incluídas ainda composições alimentícias e leite que incluem o peptídeo de interleucina-10 ou anticorpo anti-interleucina-10.
BR112017020606A 2015-03-27 2016-03-03 ?composições e métodos de uso de peptídeos de interleucina-10 e anticorpos anti-interleucina? BR112017020606A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/670,636 US20160280778A1 (en) 2015-03-27 2015-03-27 Compositions and methods of use of interleukin-10 peptides and anti-interleukin-10 antibodies
PCT/US2016/020590 WO2016160260A1 (en) 2015-03-27 2016-03-03 Compositions and use of interleukin-10 peptides and anti-interleukin-10 antibodies

Publications (1)

Publication Number Publication Date
BR112017020606A2 true BR112017020606A2 (pt) 2018-07-17

Family

ID=55586417

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020606A BR112017020606A2 (pt) 2015-03-27 2016-03-03 ?composições e métodos de uso de peptídeos de interleucina-10 e anticorpos anti-interleucina?

Country Status (5)

Country Link
US (2) US20160280778A1 (pt)
EP (1) EP3273979A1 (pt)
AU (1) AU2016243967B2 (pt)
BR (1) BR112017020606A2 (pt)
WO (1) WO2016160260A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652457B2 (en) 2012-07-13 2014-02-18 Wisconsin Alumni Research Foundation Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection
US20150037277A1 (en) 2013-08-02 2015-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Methods of reducing salmonella in poultry
AU2018278202B2 (en) 2017-05-30 2024-05-09 Agrivida, Inc. Immunomodulating transgenic plants and related methods
ES2940650T3 (es) 2017-09-12 2023-05-10 Wisconsin Alumni Res Found Péptidos del receptor 2 de interleucina-10, anticuerpos, composiciones y métodos de uso de los mismos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US5741489A (en) 1996-05-24 1998-04-21 Anitox Corporation Passively administered antibody that enhances feed conversion efficiency
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6608172B1 (en) 2000-06-09 2003-08-19 Good Biotech Corporation Isolation of IgY (ΔFc) antibodies
WO2004091519A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
US20060228448A1 (en) 2005-04-11 2006-10-12 The Iams Company Pet food compositions comprising two components
WO2007025333A1 (en) 2005-08-30 2007-03-08 Commonwealth Scientific And Industrial Research Organisation Bacterial delivery of biologically active polypeptides
WO2008086621A1 (en) 2007-01-19 2008-07-24 Iri Separation Technologies Inc. A method for commercial isolation of egg yolk igy, its product, and uses of the product
US9475839B2 (en) 2010-05-11 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
US8652457B2 (en) * 2012-07-13 2014-02-18 Wisconsin Alumni Research Foundation Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection
US20150037277A1 (en) 2013-08-02 2015-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Methods of reducing salmonella in poultry
US9821028B2 (en) 2014-07-11 2017-11-21 Wisconsin Alumni Research Foundation Methods of controlling parasitic worms in animals
CN108513593A (zh) 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位
ES2940650T3 (es) 2017-09-12 2023-05-10 Wisconsin Alumni Res Found Péptidos del receptor 2 de interleucina-10, anticuerpos, composiciones y métodos de uso de los mismos

Also Published As

Publication number Publication date
US11319367B2 (en) 2022-05-03
WO2016160260A1 (en) 2016-10-06
AU2016243967A1 (en) 2017-10-12
EP3273979A1 (en) 2018-01-31
US20160280778A1 (en) 2016-09-29
US20200031921A1 (en) 2020-01-30
AU2016243967B2 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018003665A2 (pt) métodos e composições para vetores virais de evasão de anticorpo
GT201200271A (es) Proteínas que se unen al tnf-a
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112013033258A2 (pt) moléculas de ligação de anti-alfa sinucleína
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
BR112017020606A2 (pt) ?composições e métodos de uso de peptídeos de interleucina-10 e anticorpos anti-interleucina?
BR112016030774A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo, métodos para redução da quantidade de protofibrilas de ?? em um indivíduo, para tratamento e/ou para profilaxia de uma doença, para medição da quantidade de protofibrilas de ?? e/ou de proteína ?? agregada em uma pessoa, e para diagnóstico de uma doença, e, composição farmacêutica
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
BR112014024751A2 (pt) antígenos de clostridium difficile
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112017008952A2 (pt) métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
BR112015018035A2 (pt) anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
BR112018008900A2 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
UA117657C2 (uk) Антитіло до трансглютамінази 2 (tg2)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements